JPMorgan Chase enters the back half of August with the stock touching new ground, analysts nudging targets higher still, and short sellers continuing their retreat — a setup where the most interesting question is how much further the Street's consensus can chase the price.
The week's standout move came from Wells Fargo's Mike Mayo, who raised his target to $390 from $375 just this week while maintaining his Overweight rating. That follows UBS lifting to $400 on August 3 and a wave of post-Q2 upgrades from BofA ($420), Barclays ($420), and RBC ($370) in mid-July. The direction of travel across the Street is uniformly upward. Bulls point to JPMorgan's diversified revenue model, best-in-class management, and resilient net interest margins after Q2 net income rose 25% year-over-year. Bears flag the risk of rate cuts compressing net interest income and rising expense pressures over the medium term. The consensus price target now sits at $374.57 against a close of $362.84 — implied upside of roughly 3.2%, down from the 4.6% flagged in last week's note as the stock has continued to close the gap. The PE has edged up to 14.7, and price-to-book is at 2.51. Both multiples have risen modestly over the past 30 days, consistent with a stock being re-rated rather than merely following earnings. Factor scores add texture: EPS momentum over both 30 and 90 days ranks in the 93rd and 88th percentile respectively, and the dividend score sits at the 96th percentile — a reminder that income investors remain well-supported here.
Positioning is about as relaxed as it gets for a large-cap bank. Short interest dropped sharply early in the week, falling from around 30 million shares to just under 27.8 million by August 13 — a weekly decline of roughly 8.6% — leaving short interest at just 1.0% of the free float. That is the quietest reading in months. Borrow conditions reflect the same picture: cost to borrow fell 36% over the week to 0.24%, near a 30-day low, while share availability is effectively unlimited, with over 2.1 billion shares available to lend. The ORTEX short score has also eased to 30.8, drifting lower from 31.3 earlier in the month as short-side pressure dissipates. Options are equally calm: the put/call ratio sits at 1.13, fractionally above its 20-day average of 1.12 and well within one standard deviation of normal. At the 52-week low of 0.96 and high of 1.47, the current reading is squarely in the middle — no hedging urgency, no squeeze pressure. Positioning overall looks constructive rather than defensive.
The peer group reinforced JPMorgan's resilience this week. BAC gained 2.1% and WFC 1.8%, while KEY and CFG led the regional pack with gains of 2.6% and 2.8% respectively. JPMorgan's 1.5% weekly gain was broadly in line — not the standout mover, but consistent with a stock that has already done its heavy lifting post-earnings. The institutional base is stable: BlackRock added 1.5 million shares in the most recent reporting period, and State Street added 1.5 million as well, while Vanguard trimmed a negligible 22,000 shares. Insider activity since May has been routine sell-program traffic from divisional CEOs and the General Counsel — all small parcels, all low significance scores — with nothing that changes the ownership narrative.
Earnings are next scheduled for October 13. The last two Q2 prints produced a 3.7% single-day gain and a 0.4% move respectively on Q1 2026 — both positive, suggesting the market has been rewarding rather than fading JPMorgan's results. With the stock now 5.8% higher over the past month and analyst targets still being revised upward, the October print will be watched less for the headline beat and more for any commentary on rate trajectory, credit quality, and whether the investment banking momentum that drove Q2's outsized net income holds into year-end.
See the live data behind this article on ORTEX.
Open JPM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
